Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy (Small 36/2023)

Abstract

Enhanced Hepatocellular Carcinoma Therapy First-line hepatocellular carcinoma treatment is sorafenib, but effectiveness of sorafenib is relatively low due to a lack of tumor-targeted accumulation and a lack of therapeutic efficacy. In article number 2301149, Yuan Huang and co-workers design orally administered butyrate-modified nanoparticles, which could strongly bind to monocarboxylate transporter 1 (MCT-1) receptors and efficiently penetrate the intestinal epithilium to deliver ferroptosis inducers for the treatment of liver tumors by pronounced ferroptosis damage.

Topics & Concepts